Related Experiment Video
Updated: Apr 17, 2026
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy
Kimberly A Kraynyak1, Angela Bodles-Brakhop1, Mark Bagarazzi2
1Inovio Pharmaceuticals, 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA, 19462, USA.
Abstract:
Cancer is a worldwide leading cause of death, and current conventional therapies are limited. The search for alternative preventive or therapeutic solutions is critical if we are going to improve outcomes for patients. The potential for DNA vaccines in the treatment and prevention of cancer has gained great momentum since initial findings almost 2 decades ago that revealed that genetically engineered DNA can elicit an immune response. The combination of adjuvants and an effective delivery method such as electroporation is overcoming past setbacks for naked plasmid DNA (pDNA) as a potential preventive or therapeutic approach to cancer in large animals and humans. In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance of adjuvants and electroporation with emphasis on prostate, melanoma, and cervical cancer.
Insights
DNA cancer vaccines show promise for preventing and treating cancer. Advances in adjuvants and electroporation are overcoming challenges for DNA vaccines, offering new therapeutic options.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer remains a leading global cause of death with limited conventional therapies.
- DNA vaccines have emerged as a promising alternative, leveraging the immune response elicited by genetically engineered DNA.
- Overcoming previous limitations of naked plasmid DNA (pDNA) is crucial for effective cancer immunotherapy.
Purpose of the Study:
- To review recent advances in DNA cancer vaccines.
- To discuss current preclinical data on DNA cancer vaccine efficacy.
- To highlight the importance of adjuvants and electroporation in DNA cancer vaccine development.
Main Methods:
- Focus on novel advances in DNA cancer vaccine technology.
- Analysis of preclinical data for DNA cancer vaccines.
- Emphasis on the role of adjuvants and electroporation for DNA delivery.
Main Results:
- DNA vaccines demonstrate potential for cancer treatment and prevention.
- Adjuvants and electroporation enhance the efficacy of DNA cancer vaccines.
- Preclinical data support the use of DNA vaccines in large animals and humans.
Conclusions:
- DNA cancer vaccines, enhanced by adjuvants and electroporation, represent a significant advancement in cancer immunotherapy.
- Further research and clinical trials are warranted to fully realize the potential of DNA cancer vaccines for prostate, melanoma, and cervical cancers.
- The combination of DNA technology with effective delivery systems offers a viable strategy to improve patient outcomes in oncology.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...